Francesco Santini Division of Cardiac Surgery, IRCCS San Martino – IST University of Genova Medical School, Italy Lo Scompenso Cardiaco Avanzato: la riparazione transcatetere della valvola mitrale, l’assistenza meccanica, e….altro.
Francesco Santini
Division of Cardiac Surgery, IRCCS San Martino – ISTUniversity of Genova Medical School, Italy
Lo Scompenso Cardiaco Avanzato:la riparazione transcatetere della valvola mitrale,
l’assistenza meccanica,e….altro.
European Journal of Heart Failure 2007;9:684–694
A group of patients for whom symptoms limit daily life despite usual recommendedtherapies and for whom lasting remission into less symptomatic disease is unlikely.
Selected Prognostic Models in HF
Heart Failure Survival Score
Seattle Heart Failure Model
EVEREST Risk Model
EFFECT
ADHERE
ESCAPE Discharge Score
Left ventricular systolic dysfunction
Each year cardiovascular disease (CVD) causes over 4 million deaths in Europe and over 1.9 million deaths in the European Union (EU).
Just under half of all deaths from CVD in both men and women are from CHD
One in five men (20%) and over one in five women (22%) die from the disease;
From the: European Cardiovascular Disease Statistics (2012 ed.) British Heart Foundation Health Promotion Research Group - Department of Public Health, University of Oxford
Am J Cardiol 2002;90:101–107
Circulation. 2005;112[suppl I]:I-344–I-350
Preoperative evaluation of myocardial viability in this group of patients using PET scanning or dobutamine echocardiography might additionally improve outcomes of this surgical approach.
Circulation. 2008;117:103-114
Viability = dysfunctional myocardium subtended by diseased coronary arteries withlimited or absent scarring that therefore has the potential for functional recovery.
Myocardial stunning = dysfunction can persist for several hours after transientnonlethal ischemia but eventually is followed by full functional recovery.
Myocardial hibernation = Viable myocytes that are hypocontractile secondary toongoing ischemia; these myocytes remain poorly functional until the oxygen supplyand demand imbalance can be rectified, usually by revascularization.
[even extreme degrees of wall thinning do not necessarily indicate the absence ofviability]
Algorithms for identifying and treating patients withCAD and chronically dysfunctional but viable myocardium
Circulation. 2008;117:103-114
Pres
erve
d C
ell
C
ontra
ctile
Cel
l Mem
bran
e M
etab
olis
m
R
eser
ve
I
nteg
rity
European Heart Journal August 29, 2014
Symptoms and/or signs of congestive heart failurewith abnormal left ventricular function
(clinical examination and echocardiography)
CAD+ CAD-
Assess myocardial viabilitywith technique available
Investigate alternativeaetiologies (DCM, valve disease, etc.)
No evidence of viabilityor viability in <25% of LV
Presence of significant viabilityin segments subtented by
stenotic coronaries
Medical treatment,CRT, ICD, LVAD
Coronary revascularizationby PCI or CABG
Circulation. 2008;117:103-114
Off-pump CABG
To perform coronary surgery on a
beating heart
Heart-lung machine not used
Stabilizer / Shunts
Less overall “trauma”
? Complete revascularization
Prog Cardiovasc Dis 2011;54:115-131
Patients undergoing CABG for HF with LV dysfunction(EF<30%):- operative mortality ranges from 1.6% to 11%
[perioperative complication rate approaching 65% (54% cardiac in nature)]
- 5-year survival 60% - 80%- 10-year “ 40% - 80%
Improvement in:
- LVEF - NYHA FC- disabling angina- freedom from recurrence of HF - “ “ hospitalization for HF exacerbations - overall quality of life
Ischemic Cardiomyopathy
Secondary (functional) Mitral Regurgitation:The mitral valve structure is normal and valve incompetence is related to severeLV dysfunction (Ischemic / Non-Ischemic)
Annular dilatation
Loss of systolic annular contraction
Increased LV size
PM dysfunction
PM migration
Type IIIb : Restricted leafletmotion duringsystole
Type IIIb : Restricted leafletmotion duringsystole
MR begets MR
Persistent MR is associated with a poor prognosis
Circulation 2009;120:1474-1481
viable myocardium papillary muscle dyssynchrony < MV coaptation depth(reverse LV remod) (<60msec)
Beneficial effect of concomitant CABG and MVR:
Acceptable perioperative mortality of 0.8% to 11% , and declining.
5-year survival between 51% - 83%, and improving.
Concomitant CABG and MVR achieve superior reduction in MRthan CABG alone in moderate to severe MR.
Concomitant CABG and MVR have been associated with improved:- LVEF- LVESV /LVEDV, LV sphericity index- NYHA and QoL
….no studies, however, haveshown a clear survival benefit.
European Heart Journal (2012) 33, 2451–2496
http://circ.ahajournals.org
1. Annular dilatation and flattening
2. Papillary muscle (PM) dysfunction
3. Leaflet tethering
4. LV dysfunction, dilatation, and free wall kinetic abnormalities
5. Closing forces
Undersized (or ‘restrictive’) annuloplasty- complete, rigid , 3-D, asymmetric rings- coaptation length of at least 8 mm
Resection of the secondary chordae
Repositioning of the papillary muscle
Leaflet augmentation
Concomitant LV restoration procedureMV repair
Heart Fail Rev 2013
Heart Fail Rev 2013
LV restoration procedure
(
Anteroseptal MI, dilated LV (EDVi < 100mL/m2), depressed LVEF (<20%),LV regional dyskinesis or akinesis > 30% of ventricular perimeterangina, heart failure, arrhyhtmias, inducible ischemia
European Heart Journal(2013) 34, 1323–1334
The STICH trial design
hypothesis 1:added value of revascularization over OMT
hypothesis 2:the benefit of adding SVR to CABG
issue 3:the impact of determining myocardial viability prior to revascularization
Predictors of MR after repair
Nat. Rev. Cardiol. 9, 133–146 (2012)
Mitral Valve Replacement
Types of Prostheses: the choice has to be individualized
Excellent durability; Good overall performance (avoiding physical hazards)ü Age group 40 – 65 yearsLife-long anticoagulation (complication rate 0.3-6.8/100 pt-yr)Thromboembolic events, perivalv. leakage, hemolysis, endocarditisRisk of chronic warfarin
Elderly patients (>65 yrs) [in sinus rhythm (...)]Freedom from anticoagulationThromboembolic events, perivalvular leakage, endocarditisControindicated in chronic renal failureLimited durability [SVD] (more rapid degeneration < 45 yrs )
Circulation. 1999;100[suppl II]:II-90 –II-94Reduced systolic wall stress
- Complete
- Partial
J Thorac Cardiovasc Surg 2013;145:128-39
N Engl J Med 2014;370:23-32.
Prog Cardiovasc Dis 2011;54:115-131
- operative mortality ranges from 1% to 8%[perioperative complication: MI (2.5%), IABP (25%), dialysis (7.5%), bleeding (5%)]
- 5-year survival 50% - 70%
Improvement in:
- LVEF - NYHA FC- MR grade- ventricular sphericity- 6-minute walk time
Nonischemic Cardiomyopathy
G.A. 81aaM.R. 83aa
Percutaneous mitral valve repair using the MitraClip® device
N Engl J Med 2011;364:1395-406
Although percutaneous repair was less effective at reducing mitralregurgitation than conventional surgery, the procedure wasassociated with superior safety and similar improvements in clinicaloutcomes.
http://circ.ahajournals.org
Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395-406.
Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12–month results with catheter-based mitral valve leaflet repair: the EVEREST II (EndovascularValve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol. 2012;59:130-9.
Lim DS, Reynolds MR, Feldman T, et al. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitralregurgitation following transcatheter mitral valve repair with the Mitra- Clip(R) system. J Am Coll Cardiol 2013
J Am Coll Cardiol 2013;62:e147–239
JACC 2014;64:172-81
OUTCOMES BY DMR AND FMR CAUSES
Both FMR and DMR causes were represented, with FMR present in the majority of patients (70.1%). DMR patients were older, on average, than FMR patients (by 9 years), but the 2 groups were otherwise comparable. Safety outcomes were similar between the 2 groups, and both of the groups experienced improvements in effectiveness measures.
COAPT
RESHAPE-HF 2
MITRA-France
MATTERHORN (F MR)
HIRIDE (D MR)
Improvements:• IM grade• NYHA Class • LV
remodeling• QoL
• Patient selection• Interdisciplinary Heart Team• Timing• Environment• Learning Curve• Hospital Center• Scientific Registries
Heart Transplantation is the “gold standard” treatment for CHF …albeit its inability to serve to the current demand.
51
• Completamento dell’anastomosi atriale destra (tecnica standard)
The increasing routine use of ventricular assist devices (VADs) to keep patients aliveuntil heart transplantation paved the way to their clinical use as an establishedtreatment for end-stage heart failure (DT).
imbalance between supply and demand
European Society of Cardiology (ESC) guidelines for the use of LVAD therapy
Eur J Heart Fail 2012;14:803-69
The Destination Therapy SAGA
The Interagency Registry for Mechanically Assisted Circulatory Support(Intermacs) is a North American registry established in 2005 for patients who arereceiving mechanical circulatory support device therapy to treat advanced heartfailure.
Intermacs was established as a joint effort of :
National Heart, Lung and Blood Institute (NHLBI), Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services, Clinicians, Scientists,Industry representatives.
University of Alabama at Birmingham
www.uab.edu/medicine/intermacs
J Heart Lung Transplant 2009;28:535–41
Pulsatile / Volume Displacement
Varying the rate can increase flow/output and change ventricular dimension and volume
Continuous / Rotary
Varying the speed of the rotor can increase flow/output and change ventricular dimension and volume
69
Heart Mate III (HM II) (Thoratec Inc.USA/St Jude)) Berlin Heart Incor (Berlin Heart AG, Germany) DuraHeart (Terumo, USA) HeartWare Ventricular Assist System (HeartWare Inc. USA)
continuous centrifugal-flow pump
Curr Opin Cardiol 2013, 28:223–233
Curr Opin Cardiol 2013, 28:223–233
In recent series usingcontinuous flow devices theincidence of RVF is between20 and 40%.
Evaluation of pre-operativerisk factors for post-operativeRHF.
Risk scoring systems:
Matthews’score
Fitzpatrick’s score
Drakos’ score
Curr Opin Cardiol 2013, 28:223–233
CARMATSynCardia TAH (ex Jarvik-7-CardioWest)
Abiomed AbioCor TAH
Total Artificial Heart
It is mostly used as a “bridge to transplant”. The indications are reserved forpatients waiting for a heart transplant for which any other type of assistance isexcluded.
Patients with different devices for DT
Prof. Francesco Santini Divisione e Cattedra di CardiochirurgiaUniversità degli Studi di [email protected]
Find the appropriate time to discuss and evaluate preferences,compliance, prognosis, and medical options with your patients;
Periodical systematic “heart failure review” with HF-patientsshouldinclude discussion of current and potential therapies for bothanticipated and unanticipated events, in a multidisciplinary fashion;
Intercept HF progression, since a timely indication is the key tosuccess !